Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: A randomized controlled trial

Alison Strawford, Theresa Barbieri, Marta Van Loan, Elizabeth Parks, Don Catlin, Norman Barton, Richard Neese, Mark Christiansen, Janet King, Marc K. Hellerstein

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Context: Repletion of lean body mass (LBM) that patients lose in human immunodeficiency virus (HIV) infection has proved difficult. In healthy, HIV- seronegative men, synergy between progressive resistance exercise (PRE) and very high-dose testosterone therapy has been reported for gains in LBM and muscle strength. Objective: To determine whether a moderately supraphysiologic androgen regimen, including an anabolic steroid, would improve LBM and strength gains of PRE in HIV-infected men with prior weight loss and whether protease inhibitor antiretroviral therapy prevents lean tissue anabolism. Design: Double-blind, randomized, placebo-controlled trial; post hoc analysis for effect of HIV-protease inhibitor therapy conducted from January to October 1997. Setting: Referral center in San Francisco, Calif. Patients: Volunteer sample of 24 eugonadal men with HIV-associated weight loss (mean, 9% body weight loss), recruited from an AIDS clinic and by referral and by advertisement. Intervention: For 8 weeks, all subjects received supervised PRE with physiologic intramuscular testosterone replacement (100 mg/wk) to suppress endogenous testosterone production. Randomization was between an anabolic steroid, oxandrolone, 20 mg/d, and placebo. Main Outcome Measures: Lean body mass, nitrogen balance (10-day metabolic ward measurements), body weight, muscle strength, and androgen status. Results: Twenty-two subjects completed the study (11 per group). Both groups showed significant nitrogen retention and increases in LBM, weight, and strength. The mean (SD) gains were significantly greater in the oxandrolone group than in the placebo group (5.6 [2.1] vs 3.8 [1.8]g of nitrogen per day [P=.05]; 6.9 [1.7] vs 3.8 [2.9] kg of LBM [P = .005]; greater strength gains for various upper and lower body muscle groups by maximum weight lifted [P = .02-.05] and dynamometry [P = .01-.05]). The mean (SD) high-density lipoprotein cholesterol level declined 0.25 (0.14) mmol/L (9.8 [5.4] mg/dL) significantly in the oxandrolone group (P < .001 compared with placebo). Results were similar whether or not patients were taking protease inhibitors. One subject in the oxandrolone group discontinued the study because of elevated liver function test results. Conclusions: A moderately supraphysiologic androgen regimen that included an anabolic steroid, oxandrolone, substantially increased the lean tissue accrual and strength gains from PRE, compared with physiologic testosterone replacement alone, in eugonadal men with HIV-associated weight loss. Protease inhibitors did not prevent lean tissue anabolism.

Original languageEnglish (US)
Pages (from-to)1282-1290
Number of pages9
JournalJournal of the American Medical Association
Volume281
Issue number14
DOIs
StatePublished - Apr 14 1999
Externally publishedYes

Fingerprint

Oxandrolone
Androgens
Weight Loss
Randomized Controlled Trials
Testosterone Congeners
HIV
Exercise
Protease Inhibitors
Testosterone
Placebos
Nitrogen
Body Weight
Muscle Strength
Therapeutics
Referral and Consultation
San Francisco
Liver Function Tests
Virus Diseases
Random Allocation
HDL Cholesterol

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss : A randomized controlled trial. / Strawford, Alison; Barbieri, Theresa; Van Loan, Marta; Parks, Elizabeth; Catlin, Don; Barton, Norman; Neese, Richard; Christiansen, Mark; King, Janet; Hellerstein, Marc K.

In: Journal of the American Medical Association, Vol. 281, No. 14, 14.04.1999, p. 1282-1290.

Research output: Contribution to journalArticle

Strawford, A, Barbieri, T, Van Loan, M, Parks, E, Catlin, D, Barton, N, Neese, R, Christiansen, M, King, J & Hellerstein, MK 1999, 'Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: A randomized controlled trial', Journal of the American Medical Association, vol. 281, no. 14, pp. 1282-1290. https://doi.org/10.1001/jama.281.14.1282
Strawford, Alison ; Barbieri, Theresa ; Van Loan, Marta ; Parks, Elizabeth ; Catlin, Don ; Barton, Norman ; Neese, Richard ; Christiansen, Mark ; King, Janet ; Hellerstein, Marc K. / Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss : A randomized controlled trial. In: Journal of the American Medical Association. 1999 ; Vol. 281, No. 14. pp. 1282-1290.
@article{9f23c65bca7c425b9d2fe2061eaec0f8,
title = "Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: A randomized controlled trial",
abstract = "Context: Repletion of lean body mass (LBM) that patients lose in human immunodeficiency virus (HIV) infection has proved difficult. In healthy, HIV- seronegative men, synergy between progressive resistance exercise (PRE) and very high-dose testosterone therapy has been reported for gains in LBM and muscle strength. Objective: To determine whether a moderately supraphysiologic androgen regimen, including an anabolic steroid, would improve LBM and strength gains of PRE in HIV-infected men with prior weight loss and whether protease inhibitor antiretroviral therapy prevents lean tissue anabolism. Design: Double-blind, randomized, placebo-controlled trial; post hoc analysis for effect of HIV-protease inhibitor therapy conducted from January to October 1997. Setting: Referral center in San Francisco, Calif. Patients: Volunteer sample of 24 eugonadal men with HIV-associated weight loss (mean, 9{\%} body weight loss), recruited from an AIDS clinic and by referral and by advertisement. Intervention: For 8 weeks, all subjects received supervised PRE with physiologic intramuscular testosterone replacement (100 mg/wk) to suppress endogenous testosterone production. Randomization was between an anabolic steroid, oxandrolone, 20 mg/d, and placebo. Main Outcome Measures: Lean body mass, nitrogen balance (10-day metabolic ward measurements), body weight, muscle strength, and androgen status. Results: Twenty-two subjects completed the study (11 per group). Both groups showed significant nitrogen retention and increases in LBM, weight, and strength. The mean (SD) gains were significantly greater in the oxandrolone group than in the placebo group (5.6 [2.1] vs 3.8 [1.8]g of nitrogen per day [P=.05]; 6.9 [1.7] vs 3.8 [2.9] kg of LBM [P = .005]; greater strength gains for various upper and lower body muscle groups by maximum weight lifted [P = .02-.05] and dynamometry [P = .01-.05]). The mean (SD) high-density lipoprotein cholesterol level declined 0.25 (0.14) mmol/L (9.8 [5.4] mg/dL) significantly in the oxandrolone group (P < .001 compared with placebo). Results were similar whether or not patients were taking protease inhibitors. One subject in the oxandrolone group discontinued the study because of elevated liver function test results. Conclusions: A moderately supraphysiologic androgen regimen that included an anabolic steroid, oxandrolone, substantially increased the lean tissue accrual and strength gains from PRE, compared with physiologic testosterone replacement alone, in eugonadal men with HIV-associated weight loss. Protease inhibitors did not prevent lean tissue anabolism.",
author = "Alison Strawford and Theresa Barbieri and {Van Loan}, Marta and Elizabeth Parks and Don Catlin and Norman Barton and Richard Neese and Mark Christiansen and Janet King and Hellerstein, {Marc K.}",
year = "1999",
month = "4",
day = "14",
doi = "10.1001/jama.281.14.1282",
language = "English (US)",
volume = "281",
pages = "1282--1290",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "14",

}

TY - JOUR

T1 - Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss

T2 - A randomized controlled trial

AU - Strawford, Alison

AU - Barbieri, Theresa

AU - Van Loan, Marta

AU - Parks, Elizabeth

AU - Catlin, Don

AU - Barton, Norman

AU - Neese, Richard

AU - Christiansen, Mark

AU - King, Janet

AU - Hellerstein, Marc K.

PY - 1999/4/14

Y1 - 1999/4/14

N2 - Context: Repletion of lean body mass (LBM) that patients lose in human immunodeficiency virus (HIV) infection has proved difficult. In healthy, HIV- seronegative men, synergy between progressive resistance exercise (PRE) and very high-dose testosterone therapy has been reported for gains in LBM and muscle strength. Objective: To determine whether a moderately supraphysiologic androgen regimen, including an anabolic steroid, would improve LBM and strength gains of PRE in HIV-infected men with prior weight loss and whether protease inhibitor antiretroviral therapy prevents lean tissue anabolism. Design: Double-blind, randomized, placebo-controlled trial; post hoc analysis for effect of HIV-protease inhibitor therapy conducted from January to October 1997. Setting: Referral center in San Francisco, Calif. Patients: Volunteer sample of 24 eugonadal men with HIV-associated weight loss (mean, 9% body weight loss), recruited from an AIDS clinic and by referral and by advertisement. Intervention: For 8 weeks, all subjects received supervised PRE with physiologic intramuscular testosterone replacement (100 mg/wk) to suppress endogenous testosterone production. Randomization was between an anabolic steroid, oxandrolone, 20 mg/d, and placebo. Main Outcome Measures: Lean body mass, nitrogen balance (10-day metabolic ward measurements), body weight, muscle strength, and androgen status. Results: Twenty-two subjects completed the study (11 per group). Both groups showed significant nitrogen retention and increases in LBM, weight, and strength. The mean (SD) gains were significantly greater in the oxandrolone group than in the placebo group (5.6 [2.1] vs 3.8 [1.8]g of nitrogen per day [P=.05]; 6.9 [1.7] vs 3.8 [2.9] kg of LBM [P = .005]; greater strength gains for various upper and lower body muscle groups by maximum weight lifted [P = .02-.05] and dynamometry [P = .01-.05]). The mean (SD) high-density lipoprotein cholesterol level declined 0.25 (0.14) mmol/L (9.8 [5.4] mg/dL) significantly in the oxandrolone group (P < .001 compared with placebo). Results were similar whether or not patients were taking protease inhibitors. One subject in the oxandrolone group discontinued the study because of elevated liver function test results. Conclusions: A moderately supraphysiologic androgen regimen that included an anabolic steroid, oxandrolone, substantially increased the lean tissue accrual and strength gains from PRE, compared with physiologic testosterone replacement alone, in eugonadal men with HIV-associated weight loss. Protease inhibitors did not prevent lean tissue anabolism.

AB - Context: Repletion of lean body mass (LBM) that patients lose in human immunodeficiency virus (HIV) infection has proved difficult. In healthy, HIV- seronegative men, synergy between progressive resistance exercise (PRE) and very high-dose testosterone therapy has been reported for gains in LBM and muscle strength. Objective: To determine whether a moderately supraphysiologic androgen regimen, including an anabolic steroid, would improve LBM and strength gains of PRE in HIV-infected men with prior weight loss and whether protease inhibitor antiretroviral therapy prevents lean tissue anabolism. Design: Double-blind, randomized, placebo-controlled trial; post hoc analysis for effect of HIV-protease inhibitor therapy conducted from January to October 1997. Setting: Referral center in San Francisco, Calif. Patients: Volunteer sample of 24 eugonadal men with HIV-associated weight loss (mean, 9% body weight loss), recruited from an AIDS clinic and by referral and by advertisement. Intervention: For 8 weeks, all subjects received supervised PRE with physiologic intramuscular testosterone replacement (100 mg/wk) to suppress endogenous testosterone production. Randomization was between an anabolic steroid, oxandrolone, 20 mg/d, and placebo. Main Outcome Measures: Lean body mass, nitrogen balance (10-day metabolic ward measurements), body weight, muscle strength, and androgen status. Results: Twenty-two subjects completed the study (11 per group). Both groups showed significant nitrogen retention and increases in LBM, weight, and strength. The mean (SD) gains were significantly greater in the oxandrolone group than in the placebo group (5.6 [2.1] vs 3.8 [1.8]g of nitrogen per day [P=.05]; 6.9 [1.7] vs 3.8 [2.9] kg of LBM [P = .005]; greater strength gains for various upper and lower body muscle groups by maximum weight lifted [P = .02-.05] and dynamometry [P = .01-.05]). The mean (SD) high-density lipoprotein cholesterol level declined 0.25 (0.14) mmol/L (9.8 [5.4] mg/dL) significantly in the oxandrolone group (P < .001 compared with placebo). Results were similar whether or not patients were taking protease inhibitors. One subject in the oxandrolone group discontinued the study because of elevated liver function test results. Conclusions: A moderately supraphysiologic androgen regimen that included an anabolic steroid, oxandrolone, substantially increased the lean tissue accrual and strength gains from PRE, compared with physiologic testosterone replacement alone, in eugonadal men with HIV-associated weight loss. Protease inhibitors did not prevent lean tissue anabolism.

UR - http://www.scopus.com/inward/record.url?scp=0033553201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033553201&partnerID=8YFLogxK

U2 - 10.1001/jama.281.14.1282

DO - 10.1001/jama.281.14.1282

M3 - Article

C2 - 10208143

AN - SCOPUS:0033553201

VL - 281

SP - 1282

EP - 1290

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 14

ER -